Study guide
10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols
Key Takeaways Explain This Topic AI
One unit of Packed Red Blood Cells (PRBCs, ~300 mL, Hct 55–65%) increases an adult hemoglobin by ~1.0 g/dL and hematocrit by ~3%; restrictive transfusion triggers (Hb <7.0 g/dL in stable/critically ill, Hb <8.0 g/dL in orthopedic/cardiovascular surgery, and Hb <8.0–9.0 g/dL in active acute coronary syndromes) optimize clinical outcomes and minimize transfusion-related risks.
Stored PRBCs develop progressive biochemical 'storage lesions' characterized by depletion of 2,3-DPG (shifting the oxyhemoglobin dissociation curve to the left and impeding tissue oxygen unloading), depletion of ATP, progressive acidosis (pH <6.5), and extracellular potassium leakage (up to 20–30+ mEq/L by day 35–42).
Specific component dosing and triggers: FFP (10–15 mL/kg, triggers: INR >1.5–2.0 or PT >1.5x control with active bleeding), Platelets (1 apheresis unit raises count by 30,000–50,000/µL; triggers: <50,000/µL for major surgery, <100,000/µL for neurosurgery/cardiac surgery), and Cryoprecipitate (10-unit pool supplies 1.5–2.5 g fibrinogen, raising levels by 50–70 mg/dL; trigger: fibrinogen <150–200 mg/dL).
Massive Transfusion Protocol (MTP)—activated when >10 units PRBCs/24h or >4 units/1h are required—mandates a balanced 1:1:1 ratio (PRBCs : FFP : Platelets) to recreate whole blood clotting properties and combat the lethal triad of hypothermia, acidosis, and coagulopathy.
Transfusion-Related Acute Lung Injury (TRALI)—the leading cause of transfusion-related mortality—is an antibody-mediated (anti-HLA/HNA) non-cardiogenic pulmonary edema with normal CVP/BNP presenting within 6 hours, whereas Transfusion-Associated Circulatory Overload (TACO) is hydrostatic pulmonary edema characterized by hypervolemia, hypertension, elevated CVP/BNP, and rapid response to diuresis.
Last updated: August 2026
10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols
Allogeneic blood transfusion is a lifesaving intervention that carries significant immunological, infectious, and metabolic risks. In modern anesthetic practice, hemotherapy has evolved from empirical whole-blood administration to targeted, component-specific replacement guided by evidence-based transfusion triggers, restrictive guidelines, and structured massive transfusion protocols.
1. Blood Component Characteristics, Dosing & Evidence-Based Triggers
Whole blood is fractionated into individual therapeutic components: Packed Red Blood Cells (PRBCs), Fresh Frozen Plasma (FFP), Platelets, and Cryoprecipitate. +-------------------------------------------------------------------------+
- | BLOOD COMPONENT SUMMARY & EXPECTED YIELD |
- +-------------------+--------------------+--------------------------------+
- | Blood Component | Unit Volume / Hct | Expected Clinical Yield |
- +-------------------+--------------------+--------------------------------+
- | PRBCs | ~300 mL (Hct 60%) | +1.0 g/dL Hb / +3% Hct per unit|
- | FFP | 200 - 250 mL | +20 - 30% factor levels (10-15)|
- | Platelets (Aph) | 250 - 300 mL | +30,000 - 50,000/uL per unit |
- | Cryoprecipitate | 10-15 mL/unit pool | +50 - 70 mg/dL fibrinogen (10u)|
- +-------------------+--------------------+--------------------------------+
- Detailed Component Specifications
- 1. Packed Red Blood Cells (PRBCs)
Composition: Centrifuged from whole blood; volume ≈ 250 − 350 mL \approx 250 - 350\text{ mL} ≈ 250 − 350 mL with a Hematocrit of 55 − 65 % 55 - 65\% 55 − 65% (in additive solution AS-1, AS-3, or AS-5). Stored at 1 − 6 ∘ C 1 - 6^\circ\text{C} 1 − 6 ∘ C with a shelf-life of 35 days (CPDA-1) or 42 days (additive solutions).
Expected Yield: In a 70-kg adult, 1 unit of PRBCs increases Hemoglobin by ≈ 1.0 g/dL \approx 1.0\text{ g/dL} ≈ 1.0 g/dL and Hematocrit by ≈ 3 % \approx 3\% ≈ 3% .
Transfusion Triggers (AABB & ASA Practice Guidelines):
Restrictive Threshold ( H b < 7.0 g/dL Hb < 7.0\text{ g/dL} H b < 7.0 g/dL ): Indicated for hospitalized, hemodynamically stable adult patients and critically ill ICU patients (supported by the seminal TRICC trial).
Intermediate Threshold ( H b < 8.0 g/dL Hb < 8.0\text{ g/dL} H b < 8.0 g/dL ): Indicated for patients undergoing major orthopedic surgery, cardiac surgery, or those with preexisting stable cardiovascular disease (FOCUS trial).
Higher Threshold ( H b < 8.0 − 9.0 g/dL Hb < 8.0 - 9.0\text{ g/dL} H b < 8.0 − 9.0 g/dL or < 10.0 g/dL <10.0\text{ g/dL} < 10.0 g/dL ): Indicated for patients with Acute Coronary Syndrome (ACS) , active ongoing myocardial ischemia, severe traumatic brain injury, or inadequate global oxygen delivery ( S c v O 2 < 70 % ScvO_2 < 70\% S c v O 2 < 70% ).
2. Fresh Frozen Plasma (FFP)
Composition: Prepared from centrifuged whole blood and frozen at − 18 ∘ C -18^\circ\text{C} − 1 8 ∘ C or colder within 8 hours of collection (shelf-life 1 year). Volume is ≈ 200 − 250 mL \approx 200 - 250\text{ mL} ≈ 200 − 250 mL . Contains normal plasma concentrations of all soluble clotting factors ( ≈ 1 unit/mL \approx 1\text{ unit/mL} ≈ 1 unit/mL of all factors) and 2 − 4 g/L 2 - 4\text{ g/L} 2 − 4 g/L fibrinogen.
Dosing: 10 − 15 mL/kg 10 - 15\text{ mL/kg} 10 − 15 mL/kg (typically 3–4 units in an adult), which raises coagulation factor levels by 20 − 30 % 20 - 30\% 20 − 30% (the minimum hemostatic threshold for most factors is 20 − 30 % 20-30\% 20 − 30% of normal).
Transfusion Triggers: Active microvascular bleeding in patients with documented coagulopathy ( INR > 1.5 − 2.0 \text{INR} > 1.5 - 2.0 INR > 1.5 − 2.0 or PT/aPTT > 1.5 × control \text{PT/aPTT} > 1.5\times\text{ control} PT/aPTT > 1.5 × control ), massive transfusion protocols (MTP), urgent reversal of warfarin when prothrombin complex concentrate (4F-PCC) is unavailable, or antithrombin III deficiency during heparin resistance.
Contraindications: Should never be used solely for simple volume expansion or nutritional support.
3. Platelets (Single-Donor Apheresis vs. Pooled Random-Donor)
Composition: 1 apheresis unit (collected from a single donor) contains ≥ 3.0 × 10 11 \ge 3.0 \times 10^{11} ≥ 3.0 × 1 0 11 platelets, which is equivalent to 4–6 pooled random-donor whole-blood platelet units. Volume is ≈ 250 − 300 mL \approx 250 - 300\text{ mL} ≈ 250 − 300 mL .
Storage: Stored at 20 − 24 ∘ C 20 - 24^\circ\text{C} 20 − 2 4 ∘ C (room temperature) with continuous gentle agitation (shelf-life only 5–7 days). Crucial NCE Point: Because they are stored at room temperature, platelets have the highest incidence of bacterial contamination and septic transfusion reactions among all blood products.
Expected Yield: 1 apheresis unit increases platelet count by 30 , 000 − 50 , 000 / μ L 30,000 - 50,000/\mu\text{L} 30 , 000 − 50 , 000/ μ L in a 70-kg adult.
Transfusion Triggers:
< 50 , 000 / μ L < 50,000/\mu\text{L} < 50 , 000/ μ L : Active bleeding, major noncardiac surgery, or invasive procedures (lumbar puncture, neuraxial anesthesia, central venous catheterization).
< 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L : Neurosurgery (intracranial/spinal), posterior eye surgery, or ongoing microvascular bleeding post-cardiopulmonary bypass (CPB).
< 10 , 000 − 20 , 000 / μ L < 10,000 - 20,000/\mu\text{L} < 10 , 000 − 20 , 000/ μ L : Prophylactic transfusion in non-bleeding medical/oncology patients.
Platelet Dysfunction: Irrespective of absolute count in patients on antiplatelet agents (aspirin, clopidogrel, ticagrelor) or with uremic thrombocytopathy who exhibit active microvascular bleeding.
4. Cryoprecipitate
Composition: The cold-insoluble precipitate recovered when FFP is thawed at 1 − 6 ∘ C 1 - 6^\circ\text{C} 1 − 6 ∘ C . Volume is small ( ≈ 10 − 15 mL \approx 10 - 15\text{ mL} ≈ 10 − 15 mL per single unit; usually dispensed as a 10-unit pooled bag totaling 100 − 150 mL 100-150\text{ mL} 100 − 150 mL ).
High-Yield Contents per Unit:
- Fibrinogen: 150 − 250 mg 150 - 250\text{ mg} 150 − 250 mg
- Factor VIII: 80 − 100 IU 80 - 100\text{ IU} 80 − 100 IU
- von Willebrand Factor (vWF): 40 − 70 % 40 - 70\% 40 − 70% of original plasma
- Factor XIII: 40 − 60 IU 40 - 60\text{ IU} 40 − 60 IU
- Fibronectin
Expected Yield: A standard 10-unit pool delivers 1.5 − 2.5 g 1.5 - 2.5\text{ g} 1.5 − 2.5 g of fibrinogen, raising serum fibrinogen by 50 − 70 mg/dL 50 - 70\text{ mg/dL} 50 − 70 mg/dL in a 70-kg adult.
Transfusion Triggers: Bleeding patients with hypofibrinogenemia ( < 150 − 200 mg/dL <150 - 200\text{ mg/dL} < 150 − 200 mg/dL ) in trauma, massive transfusion, cardiac surgery, postpartum hemorrhage, or DIC; dysfibrinogenemia; or von Willebrand disease / Hemophilia A when specific recombinant factor concentrates are unavailable.
Allowable Blood Loss (ABL) Calculation Estimated Blood Volume (EBV) = Weight (kg) × Average Blood Volume (mL/kg) \text{Estimated Blood Volume (EBV)} = \text{Weight (kg)} \times \text{Average Blood Volume (mL/kg)} Estimated Blood Volume (EBV) = Weight (kg) × Average Blood Volume (mL/kg)
Average Blood Volumes by Population: Premature neonate: 90 − 100 mL/kg 90-100\text{ mL/kg} 90 − 100 mL/kg ; Full-term neonate: 85 − 90 mL/kg 85-90\text{ mL/kg} 85 − 90 mL/kg ; Infant ( 3 − 12 mo 3-12\text{ mo} 3 − 12 mo ): 75 − 80 mL/kg 75-80\text{ mL/kg} 75 − 80 mL/kg ; Adult male: 70 − 75 mL/kg 70-75\text{ mL/kg} 70 − 75 mL/kg ; Adult female: 65 mL/kg 65\text{ mL/kg} 65 mL/kg ; Obese adult: calculate based on ideal body weight + 20 % + 20\% + 20% . Allowable Blood Loss (ABL) = EBV × ( Hct i n i t i a l − Hct t a r g e t ) Hct i n i t i a l \text{Allowable Blood Loss (ABL)} = \frac{\text{EBV} \times (\text{Hct}_{initial} - \text{Hct}_{target})}{\text{Hct}_{initial}} Allowable Blood Loss (ABL) = Hct ini t ia l EBV × ( Hct ini t ia l − Hct t a r g e t )
Example: An 80-kg male with initial Hct of 42 % 42\% 42% has a target Hct of 28 % 28\% 28% . EBV = 80 kg × 75 mL/kg = 6 , 000 mL \text{EBV} = 80\text{ kg} \times 75\text{ mL/kg} = 6,000\text{ mL} EBV = 80 kg × 75 mL/kg = 6 , 000 mL ABL = 6 , 000 × ( 42 − 28 ) 42 = 6 , 000 × 14 42 = 2 , 000 mL \text{ABL} = \frac{6,000 \times (42 - 28)}{42} = \frac{6,000 \times 14}{42} = \mathbf{2,000\text{ mL}} ABL = 42 6 , 000 × ( 42 − 28 ) = 42 6 , 000 × 14 = 2 , 000 mL
2. PRBC Storage Lesions & Metabolic Consequences
As packed red blood cells are stored at 1 − 6 ∘ C 1 - 6^\circ\text{C} 1 − 6 ∘ C over their 35–42 day lifespan, they undergo progressive structural, biochemical, and functional degradation collectively termed the RBC storage lesion . +-------------------------------------------------------------------------+
- | THE PRBC STORAGE LESION |
- +------------------------------------+------------------------------------+
- | BIOCHEMICAL DEGENERATION | PHYSIOLOGICAL CONSEQUENCE |
- +------------------------------------+------------------------------------+
- | Depletion of 2,3-DPG | Shifts oxyhemoglobin curve LEFT |
- | | (decreases P50, impairs O2 delivery|
- | Depletion of ATP | Loss of biconcave shape, sludging |
- | Acidosis (pH drops to <6.5) | Worsens systemic acidosis |
- | Potassium leakage (>20-30 mEq/L) | Risk of severe hyperkalemia |
- | Free Hemoglobin / Microparticles | Nitric oxide scavenging, vasospasm |
- | Citrate preservative accumulation | Chelation of ionized calcium (Ca2+)|
- +------------------------------------+------------------------------------+
- Key Biochemical Alterations
2,3-Diphosphoglycerate (2,3-DPG) Depletion: Levels of 2,3-DPG fall precipitously within 1–2 weeks of storage. Because 2,3-DPG normally stabilizes deoxyhemoglobin, its absence causes a LEFTWARD shift in the oxyhemoglobin dissociation curve (decreased P 50 P_{50} P 50 from normal 26.8 mmHg 26.8\text{ mmHg} 26.8 mmHg down to < 18 mmHg <18\text{ mmHg} < 18 mmHg ). Transfused red cells hold avidly onto oxygen, impairing tissue oxygen unloading at the microcirculatory capillary bed. (2,3-DPG regenerates in vivo over 12–24 hours post-transfusion).
ATP Depletion: Loss of ATP inhibits the N a + / K + -ATPase Na^+/K^+\text{-ATPase} N a + / K + -ATPase pump, causing cell swelling, loss of the flexible biconcave disk shape (forming rigid echinocytes and spherocytes), and phospholipid vesiculation.
Extracellular Hyperkalemia: Because the cold temperature halts the N a + / K + Na^+/K^+ N a + / K + pump, intracellular potassium leaks down its concentration gradient into the extracellular preservative fluid. Extracellular [ K + ] [K^+] [ K + ] increases from 4 mEq/L 4\text{ mEq/L} 4 mEq/L on Day 1 to > 20 − 30 mEq/L >20 - 30\text{ mEq/L} > 20 − 30 mEq/L on Day 35 (and > 50 mEq/L >50\text{ mEq/L} > 50 mEq/L in irradiated units). Rapid infusion can precipitate life-threatening hyperkalemic cardiac arrest.
Acidosis: Ongoing anaerobic glycolysis by RBCs produces lactic and pyruvic acids, causing unit pH to fall below 6.5 6.5 6.5 by the end of shelf life.
3. Massive Transfusion Protocol (MTP) & The Lethal Triad
Massive transfusion is clinically defined as:
- Replacement of ≥ 10 units \ge 10\text{ units} ≥ 10 units of PRBCs in 24 hours , OR
- Transfusion of > 4 units >4\text{ units} > 4 units of PRBCs in 1 hour with anticipated ongoing need, OR
- Replacement of > 50 % >50\% > 50% of total blood volume in 3 hours , OR
Blood loss exceeding 150 mL/min 150\text{ mL/min} 150 mL/min . +-------------------------------------------------------------------------+
- | THE TRAUMA / HEMORRHAGE LETHAL TRIAD |
- +--------------------+----------------------------+-----------------------+
- | 1. HYPOTHERMIA | 2. ACIDOSIS | 3. COAGULOPATHY |
- | - Temp < 35°C | - pH < 7.20 | - Dilutional loss |
- | - Enzyme kinetics | - Impairs clotting factor | - Platelet dysfunction|
- | drop 10% per 1°C | complex assembly on cell | - Hyperfibrinolysis |
- | - Platelet dysfnc | surfaces (VIIa drop 90%) | - Hypocalcemia |
- +--------------------+----------------------------+-----------------------+
- | ▲ |
- | Each leg of the triad exacerbates and accelerates the others |
- +-------------------------------------------------------------------------+
- Balanced Resuscitation & The 1:1:1 Strategy
Historically, massive hemorrhage was managed with crystalloid boluses followed by unguided PRBC infusions, creating profound dilutional coagulopathy. The PROPPR Trial (Pragmatic Randomized Optimal Platelet and Plasma Ratios) established modern balanced resuscitation:
Fixed 1:1:1 Ratio: Transfusion of 1 unit of PRBCs : 1 unit of FFP : 1 apheresis unit of Platelets (per 6 PRBCs/FFPs) .
Clinical Rationale: Simulates reconstituted whole blood (producing a Hematocrit of ≈ 30 % \approx 30\% ≈ 30% , platelet count > 50 , 000 / μ L >50,000/\mu\text{L} > 50 , 000/ μ L , and coagulation factor levels ≥ 60 % \ge 60\% ≥ 60% ), minimizing dilutional coagulopathy and significantly reducing early mortality from exsanguination.
4. Metabolic & Electrolyte Complications of Massive Transfusion
Complication Pathophysiologic Mechanism Clinical Manifestations Anesthetic Management
Citrate Toxicity & Hypocalcemia Banked blood contains sodium citrate ( 1.66 g/unit 1.66\text{ g/unit} 1.66 g/unit ) to chelate calcium and prevent in-vitro clotting. Rapid transfusion ( > 1 unit/5 min >1\text{ unit/5 min} > 1 unit/5 min ) or impaired hepatic metabolism (shock, hypothermia, cirrhosis) causes citrate accumulation, chelating recipient ionized C a 2 + Ca^{2+} C a 2 + . Narrow pulse pressure, hypotension, decreased cardiac contractility, elevated CVP, prolonged QTc interval , tetany, laryngospasm, ventricular arrhythmias Administer Calcium Chloride ( 1 g IV 1\text{ g IV} 1 g IV , delivers 270 mg 270\text{ mg} 270 mg elemental C a 2 + Ca^{2+} C a 2 + ) or Calcium Gluconate ( 3 g IV 3\text{ g IV} 3 g IV , delivers 270 mg 270\text{ mg} 270 mg elemental C a 2 + Ca^{2+} C a 2 + ). Maintain ionized C a 2 + > 1.0 − 1.12 mmol/L Ca^{2+} > 1.0 - 1.12\text{ mmol/L} C a 2 + > 1.0 − 1.12 mmol/L .
Hyperkalemia Hemolysis and progressive potassium leakage from stored PRBCs (up to 30 mEq/L 30\text{ mEq/L} 30 mEq/L in supernatant). Rapid infusion into central circulation overwhelms renal excretion. Peaked T waves, PR interval prolongation, widening QRS complex, loss of P wave, sine-wave pattern, asystole/VF Administer 1 g 1\text{ g} 1 g Calcium Chloride to stabilize cardiac membrane; push Regular Insulin 10 units + + + 50 mL D 50 W 50\text{ mL } D_{50}W 50 mL D 50 W ; hyperventilate (each 0.1 ↑ pH 0.1\uparrow\text{ pH} 0.1 ↑ pH lowers [ K + ] [K^+] [ K + ] by ≈ 0.5 mEq/L \approx 0.5\text{ mEq/L} ≈ 0.5 mEq/L ); albuterol nebulizer.
Hypothermia Rapid infusion of cold blood products ( 4 ∘ C 4^\circ\text{C} 4 ∘ C ) and room-temperature fluids into an open cavity under general anesthesia. Core body temperature < 35 ∘ C <35^\circ\text{C} < 3 5 ∘ C ; coagulopathy (10% drop in enzyme cascade velocity per 1 ∘ C 1^\circ\text{C} 1 ∘ C drop); shivering on emergence ( 400 % 400\% 400% increase in V O 2 VO_2 V O 2 ). Utilize high-flow rapid infusers with inline warmers (e.g., Belmont, Level 1 at 41 ∘ C 41^\circ\text{C} 4 1 ∘ C ); forced-air warming blankets; warm ambient OR temperature ( > 24 ∘ C >24^\circ\text{C} > 2 4 ∘ C ).
Acid-Base Swings Early Phase: Metabolic acidosis from lactic acid and acidic preservatives in stored blood.; Delayed Phase: Metabolic alkalosis as hepatic metabolism converts each molecule of citrate into 3 molecules of bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ). Early: myocardial depression.; Delayed: hypokalemia, compensatory hypoventilation, left-shifted oxyhemoglobin curve. Serial arterial blood gas (ABG) monitoring; avoid over-correcting early acidosis with sodium bicarbonate.
5. Adverse Transfusion Reactions & Pulmonary Complications
Adverse reactions range from mild febrile episodes to life-threatening pulmonary collapse and acute intravascular hemolysis.
TRALI vs. TACO: Differential Diagnosis (High-Yield NCE Topic)
Clinical Feature Transfusion-Related Acute Lung Injury (TRALI) Transfusion-Associated Circulatory Overload (TACO)
Primary Mechanism Immune-mediated: Donor anti-HLA or anti-human neutrophil antigen (anti-HNA) antibodies activate recipient neutrophils in pulmonary capillaries → \rightarrow → endothelial damage and non-cardiogenic capillary leak. Hydrostatic volume overload: Excessive fluid volume or rapid infusion rate exceeding cardiac and renal excretory capacity → \rightarrow → hydrostatic cardiogenic pulmonary edema.
Leading Blood Source High-plasma products (FFP, Platelets) from multiparous female donors (alloimmunized during pregnancy). Any blood product or crystalloid/colloid infusion; common in elderly, renal failure, CHF.
Timing Within 6 hours of transfusion completion (often within 1–2 hours). Within 6 hours of transfusion (often during or immediately post-infusion).
Hemodynamics Hypotension or normal blood pressure; tachycardia. Hypertension (widened pulse pressure); tachycardia.
CVP / PAOP Normal or LOW (non-cardiogenic; CVP < 10 mmHg <10\text{ mmHg} < 10 mmHg , PAOP < 18 mmHg <18\text{ mmHg} < 18 mmHg ). ELEVATED (cardiogenic; CVP > 15 mmHg >15\text{ mmHg} > 15 mmHg , PAOP > 18 mmHg >18\text{ mmHg} > 18 mmHg ).
BNP / NT-proBNP Normal or minimally elevated. Markedly elevated ( > 1.5 × >1.5\times > 1.5 × pre-transfusion baseline or > 1 , 200 pg/mL >1,200\text{ pg/mL} > 1 , 200 pg/mL ).
Body Temperature Fever / Hypothermia commonly present ( > 1 ∘ C >1^\circ\text{C} > 1 ∘ C rise). Temperature typically normal.
Edema Fluid Analysis Exudative: High protein content (fluid/plasma protein ratio > 0.7 >0.7 > 0.7 ). Transudative: Low protein content (fluid/plasma protein ratio < 0.5 <0.5 < 0.5 ).
Echocardiogram Normal LV systolic function; hyperdynamic. LV systolic/diastolic dysfunction, elevated filling pressures.
Response to Diuretics Minimal / Unresponsive (may worsen hypotension). Rapid, dramatic improvement with IV loop diuretics (furosemide).
Management Lung-protective ventilation (low V t V_t V t 6 mL/kg, PEEP), hemodynamic support with fluids/vasopressors; notify blood bank to quarantine donor products. Stop/slow transfusion, sit patient upright, administer supplemental O 2 O_2 O 2 /CPAP, give IV Furosemide ( 20 − 40 mg 20 - 40\text{ mg} 20 − 40 mg ) .
Acute Hemolytic Transfusion Reaction (AHTR)
Etiology: Intravascular destruction of transfused RBCs caused by ABO incompatibility (almost universally due to clerical/administrative misidentification of patient or blood sample). Preformed recipient IgM antibodies bind donor RBC surface antigens, activating the full complement cascade ( C 5 b − 9 C5b-9 C 5 b − 9 membrane attack complex) and triggering massive intravascular hemolysis.
Classic Triad Under General Anesthesia:
- Unexplained, Refractory Hypotension
- Hemoglobinuria (Burgundy / Dark "Cola-Colored" Urine)
- Diffuse Microvascular Oozing in the Surgical Field (DIC)
Immediate Anesthetic Management Protocol:
STOP THE TRANSFUSION IMMEDIATELY. Disconnect tubing and save all blood bags and tubing to return to the blood bank.
Re-check patient identification wristband, blood product label, and compatibility tags.
Maintain vigorous renal perfusion: Administer IV crystalloid fluids to maintain urine output ≥ 1 − 2 mL/kg/hr \ge 1 - 2\text{ mL/kg/hr} ≥ 1 − 2 mL/kg/hr to prevent precipitation of toxic acid hematin in renal tubules.
Administer osmotic diuretics ( Mannitol 12.5 − 25 g IV 12.5 - 25\text{ g IV} 12.5 − 25 g IV ) and loop diuretics ( Furosemide 20 − 40 mg IV 20 - 40\text{ mg IV} 20 − 40 mg IV ).
Alkalinize the urine by infusing Sodium Bicarbonate ( 40 − 70 mEq/L 40 - 70\text{ mEq/L} 40 − 70 mEq/L ) to maintain urine p H > 7.0 pH > 7.0 p H > 7.0 (inhibits acid hematin crystallization).
Send repeat blood samples (lavender and red top tubes) and urine samples to the blood bank for direct antiglobulin test (DAT / Coombs test), repeat crossmatching, plasma free hemoglobin, and serum haptoglobin.
Support systemic blood pressure and inotropy with vasopressors.